<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00569699</url>
  </required_header>
  <id_info>
    <org_study_id>01023019</org_study_id>
    <nct_id>NCT00569699</nct_id>
  </id_info>
  <brief_title>Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)</brief_title>
  <official_title>Phase II Trial of Combination Therapy With Bevacizumab and S-1 in Elderly Patients With Unresectable or Recurrent Colorectal Cancer (BASIC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taiho Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taiho Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether S-1 and bevacizumab are safe in the&#xD;
      treatment of unresectable or recurrent colorectal cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>every course for first three courses, then every other course</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, Response rate, Time to progression, Time to treatment failure, Overall survival, Treatment situation</measure>
    <time_frame>any time</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1, Bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1, Bevacizumab</intervention_name>
    <description>S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA &lt;1.25 m2), 50 mg (BSA &gt;1.25 to &lt;1.50 m2), or 60 mg (BSA &gt;1.50 m2).&#xD;
Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed colorectal carcinoma with inoperable, locally advanced, or&#xD;
             metastatic disease, not amenable to curative therapy&#xD;
&#xD;
          2. Measurable disease or non-measurable but assessable disease according to the Response&#xD;
             Evaluation Criteria in Solid Tumors (RECIST)&#xD;
&#xD;
          3. Patients with no previous treatment (radiotherapy or chemotherapy). Patients who have&#xD;
             received postoperative adjuvant chemotherapy are eligible if relapse is diagnosed more&#xD;
             than 180 days after the end of such treatment.&#xD;
&#xD;
          4. Treatment with FOLFIRI and FOLFOX is not indicated.&#xD;
&#xD;
          5. Age &gt;65 years&#xD;
&#xD;
          6. Life expectancy of at least 3 months&#xD;
&#xD;
          7. ECOG PS of 0, 1, or 2&#xD;
&#xD;
          8. Adequate function of major organs as defined below:&#xD;
&#xD;
               1. Hemoglobin &gt;9.0 g/dL&#xD;
&#xD;
               2. White blood cell count &gt;3,500/mm3, &lt;12,000/mm3&#xD;
&#xD;
               3. Neutrophil count &gt;1,500/mm3&#xD;
&#xD;
               4. Platelet count &gt;100,000/mm3&#xD;
&#xD;
               5. Total bilirubin &lt;1.5 mg/dL&#xD;
&#xD;
               6. AST and ALT &lt;100 U/L (&lt;200 U/L in patients with liver metastasis)&#xD;
&#xD;
               7. Serum creatinine &lt;1.2 mg/dL&#xD;
&#xD;
               8. Creatinine clearance estimate by the Cockcroft-Gault method &gt;50 mL/min&#xD;
&#xD;
          9. Able to take capsules orally.&#xD;
&#xD;
         10. No electrocardiographic abnormalities within 28 days before enrollment that would&#xD;
             clinically preclude the execution of the study, as judged by the investigator.&#xD;
&#xD;
         11. Voluntary written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Serious drug hypersensitivity or a history of drug allergy&#xD;
&#xD;
          2. Active double cancer&#xD;
&#xD;
          3. Active infections (e.g., patients with pyrexia of 38â„ƒ or higher)&#xD;
&#xD;
          4. Uncontrolled hypertension&#xD;
&#xD;
          5. Serious complications (e.g., pulmonary fibrosis, interstitial pneumonitis, heart&#xD;
             failure, renal failure, hepatic failure, or poorly controlled diabetes)&#xD;
&#xD;
          6. Moderate or severe ascites or pleural effusion requiring treatment&#xD;
&#xD;
          7. Watery diarrhea&#xD;
&#xD;
          8. Treatment with flucytosine&#xD;
&#xD;
          9. Metastasis to the CNS&#xD;
&#xD;
         10. Pregnant women, possibly pregnant women, women wishing to become pregnant, and nursing&#xD;
             mothers. Men who are currently attempting to conceive children.&#xD;
&#xD;
         11. Severe mental disorder&#xD;
&#xD;
         12. Continuous treatment with steroids&#xD;
&#xD;
         13. Urine dipstick for proteinuria should be &lt;2+&#xD;
&#xD;
         14. Thrombosis, cerebral infarction, myocardial infarction, or pulmonary embolism&#xD;
&#xD;
         15. Major surgical procedure, open biopsy, or clinically significant traumatic injury&#xD;
             within 4 weeks&#xD;
&#xD;
         16. Long-term daily treatment with aspirin (&gt;325 mg/day)&#xD;
&#xD;
         17. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of&#xD;
             bleeding&#xD;
&#xD;
         18. Judged ineligible for participation in the study by the investigator for safety&#xD;
             reasons.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroya Takiuchi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Osaka Medical College Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka Medical College Hospital</name>
      <address>
        <city>Takatsuki</city>
        <state>Osaka</state>
        <zip>569-8686</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2007</study_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>S-1</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

